An evaluation of the safety and efficacy of the calcineurin inhibitor, pimecrolimus cream 1%, in adult patients with perioral dermatitis. This study is not enrolling patients in the United States.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
124
Pimecrolimus cream 1 %
Vehicle cream (placebo)
Novartis Pharmaceuticals
Nuremberg, Germany
Reduction of the Perioral Dermatitis Severity Index
Time to disease recurrence
Response rates
Patient's quality of life assessment
Patient's disease severity assessment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.